OncoMatch/Clinical Trials/NCT06799195
Optimizing GVHD Prophylaxis After Allogeneic Hematopoietic Cell Transplantation
Is NCT06799195 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Attenuated-dose Cyclophosphamide and High-dose Cyclophosphamide for hematological malignancies.
Treatment: Attenuated-dose Cyclophosphamide · High-dose Cyclophosphamide · Sirolimus · Mycophenolate Mofetil (MMF) — This study will compare post-transplant health-related quality of life following the use of standard versus attenuated dose of post-transplant cyclophosphamide in addition to two-drug graft-versus-host disease (GVHD) prophylaxis among recipients of allogeneic hematopoietic stem cell transplant.
Check if I qualifyExtracted eligibility criteria
Cancer type
Acute Myeloid Leukemia
Acute Lymphoblastic Leukemia
Non-Hodgkin Lymphoma
Multiple Myeloma
Myelodysplastic Syndrome
Chronic Lymphocytic Leukemia
Prior therapy
Cannot have received: allogeneic stem cell transplant
Lab requirements
Kidney function
Creatinine clearance less than 40 mL/min/1.73 m² [excluded]
Liver function
Known diagnosis of liver cirrhosis or other advanced liver disease that may impact cyclophosphamide metabolism [excluded]
Cardiac function
Systolic cardiac dysfunction with an ejection fraction of less than 45% [excluded]
Known diagnosis of liver cirrhosis or other advanced liver disease that may impact cyclophosphamide metabolism. Creatinine clearance less than 40 mL/min/1.73 m². Systolic cardiac dysfunction with an ejection fraction of less than 45%.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- University of Nebraska Medical Center · Omaha, Nebraska
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify